MAPT and Alzheimer disease: In the context of AD, the focus should be on individuals at risk, such as those with MCI, subjective cognitive decline, elders with positive Aβ or tau biomarkers, APOE-ε4-carriers or healthy elderly individuals with high-risk scores [105].